Attralus
San Francisco
About Attralus
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $197.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2024)
- Website: attralus.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/attralus-89543 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.